Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

al of Atu027 in patients with solid tumours. Interim results from the trial were announced at the annual meeting of the American Society of Clinical Oncology ('ASCO') in June 2012. The results demonstrated that 10 of the 33 patients treated with Atu027 achieved stable disease at study end (three months after treatment initiation). Patient recruitment into this trial is now complete.  A total of 34 patients have been recruited into the trial which is expected to finish in July 2012 with results available shortly thereafter. To date, Atu027 has been shown to be safe and well tolerated.  The Company plans to use proceeds from this Fundraising to conduct a small Phase Ib trial using Atu027 in combination with a chemotherapy regimen, and subject to the results of this study and any necessary preclinical work, conduct a small Phase IIa trial.

Atu111

Atu111, for the treatment of acute lung injury, is the Company's most advanced drug development candidate

outside oncology. Unlike Silence oncology drug candidates, Atu111 combines Silence' DACC drug delivery system with AtuRNAi. The target for this RNAi therapeutic is undisclosed. However, pre-clinical models using the DACC delivery system have shown sustained knockdown of up to three weeks in the lung endothelium. Silence recently completed proof-of-concept studies in a pre-clinical model of acute lung injury demonstrating  encouraging results using Atu111. Based on these results, Silence plans to conduct further studies in different pre-clinical models of acute lung injury.

Liver projects

Diseases including liver fibrosis and liver cancer continue to be areas of high unmet medical need and their high prevalence in Asia mean they are of increasing interest to pharmaceutical companies. Silence has developed a novel delivery system known as DBTC that enables highly specific delivery of siRNA molecules to cells of the liver including hepatocytes. Silence therefore recently initi
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... is designed to introduce cutting edge communication technology, ... of platform upgrades. This webinar series demonstrates online ... quest to leverage web conferencing’s most innovative and ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... is about to emerge in the world of pesticides and ... to understand the implications for public health, ensure that this ... risks, researchers say in a new report. In a ... and Environmental Health , scientists from Oregon State University and ...
... Oct. 4 Amgen (Nasdaq: AMGN ) ... ,181, pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in ... and second-line treatment for metastatic colorectal cancer (mCRC), respectively, ... Oncology . "Both studies demonstrated that ...
... NEW YORK, Oct. 4 Reportlinker.com announces that ... its catalogue: Global Soft Tissue ... This report analyzes the worldwide markets ... the following segments: Cartilage Allografts, Meniscus Allografts, and ...
Cached Biology Technology:New approaches needed to gauge safety of nanotech-based pesticides 2New approaches needed to gauge safety of nanotech-based pesticides 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11Reportlinker Adds Global Soft Tissue Allografts Industry 2Reportlinker Adds Global Soft Tissue Allografts Industry 3Reportlinker Adds Global Soft Tissue Allografts Industry 4Reportlinker Adds Global Soft Tissue Allografts Industry 5Reportlinker Adds Global Soft Tissue Allografts Industry 6Reportlinker Adds Global Soft Tissue Allografts Industry 7Reportlinker Adds Global Soft Tissue Allografts Industry 8Reportlinker Adds Global Soft Tissue Allografts Industry 9Reportlinker Adds Global Soft Tissue Allografts Industry 10Reportlinker Adds Global Soft Tissue Allografts Industry 11
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... , January 22, 2015 , ... tenth year  The European Patent Office to present a ... Two British nominations to be featured: Christofer Toumazou and ... featuring former finalists and winners of the Award   ...
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its ... the G2 model. The G2 sets a higher standard for ... human capital management solution. With plug-and-play installation, touch screen interface ... clock provides a robust time collection solution for the small ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2
... called ribonucleotides become embedded in genomic DNA, which contains ... cause problems for cells. It is known that ribonucleotides ... resulting in genomic instability and altered DNA metabolism, but ... ribonucleotides. A new study provides a mechanistic explanation ...
... and colleagues have produced the most comprehensive mathematical model ... to environmental change. The research, federally ... 2 in the journal Science . ... unites various sub-disciplines of population biology, including population ecology, ...
... Los Angeles, CA (December 2nd, 2011) Most of ... new results out in the journal Clinical Rehabilitation , ... to reduce early retirement on health grounds in Finland had ... evaluative study of vocational rehabilitation, which followed 872 participants and ...
Cached Biology News:Study identifies mechanisms cells use to remove bits of RNA from DNA strands 2Powerful mathematical model greatly improves predictions for species facing climate change 2Powerful mathematical model greatly improves predictions for species facing climate change 3Costly intervention program has no measurable effect on early retirement 2Costly intervention program has no measurable effect on early retirement 3
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
... Dunbar (1994) • This book describes ... methods for preparing samples for protein ... radiometric and bioluminescence-enhanced detection systems are ... the detection and characterization of glycoprotein ...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Biology Products: